OPK

1.63

0.00% 0.00

Handel nachbörslich: 1.62 -0.010 -0.61%

Opko Health Inc (OPK)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.63

Offen:

$1.65

24-Stunden-Volumen:

1.92M

Relative Volume:

0.22

Marktkapitalisierung:

$1.22B

Einnahmen:

$581.12M

Nettoeinkommen (Verlust:

$-212.92M

KGV:

-5.9533

EPS:

-0.2738

Netto-Cashflow:

$-174.22M

1W Leistung:

+1.24%

1M Leistung:

-0.61%

6M Leistung:

+32.52%

1J Leistung:

+8.67%

1-Tages-Spanne:

$1.63

$1.67

1-Wochen-Bereich:

$1.58

$1.67

52-Wochen-Spanne:

$0.9769

$1.77

Opko Health Inc Stock (OPK) Company Profile

Firmenname

Opko Health Inc

Sektor

Healthcare (1053)

Branche

Diagnostics & Research (44)

Telefon

305-575-4181

Adresse

4400 BISCAYNE BLVD., MIAMI, FL

Mitarbeiter

2,275

Twitter

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

OPK's Discussions on Twitter

Compare OPK vs TMO, DHR, NTRA, A, IQV

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OPK Opko Health Inc	1.63	1.22B	581.12M	-212.92M	-174.22M	-0.2738
TMO Thermo Fisher Scientific Inc	684.89	253.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.97	163.77B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	404.90	58.36B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	175.96	49.61B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	273.60	45.03B	16.63B	1.39B	2.12B	8.0674

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-10-16	Hochstufung	Barrington Research	Mkt Perform → Outperform
2026-04-29	Herabstufung	Barrington Research	Outperform → Mkt Perform
2025-11-20	Eingeleitet	JP Morgan	Neutral
2025-10-31	Herabstufung	Jefferies	Buy → Hold
2025-04-25	Eingeleitet	JP Morgan	Neutral
2023-06-29	Hochstufung	Barrington Research	Mkt Perform → Outperform
2022-12-15	Eingeleitet	H.C. Wainwright	Buy
2022-01-24	Herabstufung	Barrington Research	Outperform → Mkt Perform
2021-06-21	Eingeleitet	Ladenburg Thalmann	Buy
2019-11-25	Eingeleitet	Piper Jaffray	Overweight
2018-03-02	Herabstufung	JP Morgan	Neutral → Underweight
2017-09-14	Herabstufung	JP Morgan	Overweight → Neutral
2016-06-21	Bestätigt	Standpoint Research	Buy
2016-06-03	Eingeleitet	Standpoint Research	Buy
2016-03-31	Bestätigt	Barrington Research	Outperform
2015-10-16	Eingeleitet	JP Morgan	Overweight
2015-09-11	Herabstufung	Jefferies	Buy → Hold
2015-03-03	Herabstufung	Oppenheimer	Outperform → Perform
2014-05-12	Bestätigt	Oppenheimer	Outperform
2014-03-14	Eingeleitet	Oppenheimer	Outperform
2013-11-13	Bestätigt	Ladenburg Thalmann	Buy
2013-05-30	Bestätigt	Ladenburg Thalmann	Buy
2012-10-22	Eingeleitet	Barrington Research	Outperform
2011-12-01	Bestätigt	Ladenburg Thalmann	Buy
2011-07-14	Eingeleitet	Ladenburg Thalmann	Buy

Alle ansehen

Opko Health Inc Aktie (OPK) Neueste Nachrichten

Oct 23, 2026

SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy - Zacks Investment Research

Oct 23, 2026

FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI - Zacks Investment Research

Oct 23, 2026

Oct 22, 2026

GEHC Expands Theranostics Imaging With 5 Global Collaborations - Zacks Investment Research

Oct 22, 2026

Revvity Launches Signals LabGistics to Coordinate Scientific Workflows - Zacks Investment Research

Oct 22, 2026

3 Promising Penny Stocks With Over $200M Market Cap - Simply Wall Street

Oct 22, 2026

Oct 21, 2026

Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp - PR Newswire

Oct 21, 2026

Oct 20, 2026

H.C. Wainwright keeps USD 3.00 target for OPKO Health stock - AD HOC NEWS

Oct 20, 2026

Oct 17, 2026

OPKO Health (OPK) Sells BioReference Assets On A Valuation Story That Still Divides - Yahoo Finance

Oct 17, 2026

Barrington sets USD 2.25 target for OPKO Health stock - ad-hoc-news.de

Oct 17, 2026

Is OPKO Health (OPK) Pricing In Too Much For Sales? - Yahoo Finance

Oct 17, 2026

OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - Zacks Investment Research

Oct 17, 2026

Oct 16, 2026